Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

The KAEPacity Study Analyzes Hospital Emergency and Disaster Plans From Hospitals Across Germany to Evaluate How Well Hospitals Are Prepared for Crises and Disasters Organizational Structures Communication Leadership Training Are Examined Within These Plans No Medical Intervention is Performed

NCT07440329 · tracked via the Priya Life Science Germany tracker
Sponsor
Lea Kölsch
Phase
Observational
Started
2026-03-09
Last updated
2026-03-11

Condition(s) studied

Disaster PlanningEmergency Medical ServicesGermany

Study summary

Hospital Emergency and Disaster Plans (Krankenhausalarm- und Einsatzplan-KAEP) are a central component of hospital preparedness in Germany. Despite national and international recommendations, considerable variability exists in structure, responsibilities, communication pathways, and training concepts across hospitals. This study aims to systematically analyze and compare KAEP documents from German hospitals using a structured qualitative and quantitative document analysis. The goal is to identify strengths, deficits, institutional influencing factors, and best-practice elements to support evidence-based improvements and harmonization of hospital emergency planning.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: German hospitals with a documented KAEP Institutional consent to provide KAEP documents for analysis Exclusion Criteria: Hospitals declining participation Specialized facilities without emergency or acute care services (e.g., rehabilitation clinics)

Primary outcome measure(s)

  • Maturity of Hospital Emergency Plans — Baseline
    Overall maturity of hospital emergency and disaster plans assessed using a predefined composite score. The score is calculated by aggregating four predefined domains (structure, operational processes, communication, training/exercises) each rated on a standardized 0-5 ordinal scale. Domain scores are summed to generate a single overall maturity score per hospital.
  • Derivation of Practice-Oriented Recommendations — through study completion, an average of 1 year
    Identification of strengths, weaknesses, and improvement potential across hospitals.

Trial sites (1)

FacilityCityRegionStatus
Stabsstelle Krisen- und Katastrophenmanagement Heidelberg Germany Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07440329 on ClinicalTrials.gov ↗ ← All trials in Germany